An oral anticoagulant getting developed by Bristol-Myers Squibb Company and Pfizer Inc malegra.

Apixaban more advanced than enoxaparin in reducing venous thromboembolism in total knee replacement surgery patients Apixaban, an oral anticoagulant getting developed by Bristol-Myers Squibb Company and Pfizer Inc. , was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients going through elective total knee replacement unit surgery, according today in The Lancet to the ADVANCE-2 study results published. The study results showed numerically lower rates of major and also relevant non-main bleeding in patients treated with apixaban clinically compared with those treated with enoxaparin malegra http://malegra.biz . These results didn’t meet statistical significance.